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Objectives: To determine if there is a difference in outcome between various airway
clearance techniques (ACTs) chosen by patient’s preference.
Method: 79 patients with cystic ﬁbrosis aged 6 years to 47 years who were performing
positive expiratory pressure (PEP) as their ACT changed to performing another ACT
of their choice for a period of 2 months. Pulmonary function tests (PFT), health related
quality of life and satisfaction questionnaires were administered at the beginning and
end of the 2 month period. Adherence was monitored throughout the study.
Results: The 79 participants chose the following techniques to perform, 35 modiﬁed
PD and percussion (PD&), 35 active cycle of breathing techniques (ACBT), 5 autogenic
drainage (AD), and 4 oscillating positive expiratory pressure (Osc PEP).
Over the 2 month period, there was no signiﬁcant change in PFTs in any groups.
However, all groups increased both their FVC and FEV.
Change over 2 months in each group
PD&P ACBT AD OscPEP
Age (Mean±) 10.3±3.9 11.6±3.2 12.2±2.9 9.8±3.9
FVC (Mean change) 0.06±0.17 0.08±0.2 0.02±0.24 0.05±0.17
FEV1 (Mean change) 0.04±0.15 0.05±0.14 0.02±0.21 0.11±0.11
There was a signiﬁcant difference in ages of each group, younger participants chose
PD&P while the older ones chose AD. The Cystic Fibrosis questionnaire (CFQ) data
showed no signiﬁcant difference between any of the groups in the Physical, Emotional,
Health, Weight or Respiratory domains. Adherence was extraordinarily high at 92%.
Conclusions:When participants were adherent in performing their ACT, each ACT was
as effective as the other in maintaining pulmonary function. Thus by giving CF patients
a choice of ACT, this may improve outcome.
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Adherence to treatment and its measurement remain a challenge in the treatment
of CF.
Objectives: To measure adherence to physiotherapy and to determine the usefulness
of an adherence rating scale for use by patients (Pt) and therapists (Tp) over a three
year period.
Methods: A 5 point adherence scale (5PAS) was developed with 5 = 81–100%;
4 = 61−80; 3 = 41−60; 2 = 21−40; 1 = 0−20. Pt and Tp recorded scores separately for
airway clearance therapy (ACT), inhalational therapy and exercise in the Outpatient
Clinic.
Results: With Ethics approval 151 (84males) of 206 eligible CF Clinic patients
were included. The Median (IQR) for males vs females for age was 36 (29−42) vs
34 (29−43) years; FEV1 percent predicted 67 (45−87) vs 55 (49−79; and BMI 24
(22−25) vs 21 (20−23). Physiotherapist vs patient reported scores for ACT: mean
(SD) 3.80 (1.11) vs 4.07 (1.03); Inhalational therapy: 3.83 (1.14) vs 4.33 (0.92);
Exercise: 3.53 (0.95) vs 3.90 (1.02). There were strong positive correlations between
patient and physiotherapist reported adherence scores for ACT, Inhalational Therapy
and Exercise (r = 0.783, 0.634, 0.595; p< 0.001, Kappa = 0.458, 0.465, 0.309
respectively. For Dornase Alpha there was a strong positive correlation between
patient adherence and objectively measured pharmacy dispensing scores r = 0.56,
p< 0.001 and a moderate positive correlation for physiotherapist reported scores
and pharmacy dispensing r = 0.49, p< 0.001.
Conclusion: Ratings of adherence indicated that the majority of the study popula-
tion were regarded as adherent for all treatment categories. This 5 point adherence
scale may be a useful way to quantify adherence to therapy and requires further
investigation and validation.
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Background: Short-term tolerability of inhaled hypertonic saline (HS 6%), rhD-
Nase, tobramycin and colistin in CF has been investigated before. Bronchial
hyperreactivity (BHR) however is poorly reported.
Aim: Examine the appearance of BHR related to chronic inhalation of previously
described drugs leading to cessation. Determine risk factors for appearance of BHR,
such as characteristics of speciﬁc drugs, adulthood and duration of treatment.
Method: All CF patients’ ﬁles of the University Hospital Brussels were screened
from January 2002 till October 2012 related to the use of inhaled HS 6%, rhDNase,
tobramycin and colistin after bronchodilation. Start and end date of inhalation
treatment were registered and if applicable, reason for ending inhalation.
Results: 163 (91M) patients were included with a median age of 17 years (0−61;
n <18 y = 84) and median number of inhaled drugs pp. per day was 2 (range
0−4). BHR occurred in 29 patients (17.8%), mostly in adults (26.6% vs. 9.5%
<18 y; p< 0.5) and after a median of 1086.5 days (0–3740 days). The occurrence
of BHR was signiﬁcant after inhalation of HS 6% (19.6% (p< 0.01)) and antibiotics
(tobramycin 16.2% (p< 0.01); colistin 10.1% (p< 0.5)), but not after inhalation of
rhDNase (1.4%; p = 0.61). A signiﬁcant correlation was found between number of
inhaled drugs pp. per day and the occurrence of BHR (t= 0.25; p< 0.01).
Conclusion: BHR is seen more often in adults and after chronic inhalation.
Furthermore it depends on the type of drug and increases with the number of
taken aerosols per day. These ﬁndings may be suggestive for a cumulative effect of
inhalation therapy on BHR, which cannot always be prevented with bronchodilators.
WS9.4 Non invasive ventilation as airway clearance technique
compared to PEP in adult patients with cystic ﬁbrosis
M.C. Rodriguez Hortal1, L. Hjelte1. 1Karolinska University Hospital, Stockholm,
Sweden
Objectives: Chest physiotherapy is crucial for evacuating airway secretions and for
slowing down the rate of deterioration in pulmonary function. Many CF patients
show increased energy expenditure, oxygen desaturation, fatigue and dyspnoea
during chest physiotherapy. Non invasive ventilation (NIV) with Bilevel-PAP
(positive airway pressure) reduces respiratory muscle work, prevents respiratory
muscle fatigue and could thus be a good alternative for very ill patients who need
extra support during airway clearance.
The aim of the study was to ﬁnd out if NIV is as effective as PEP on airway
clearance and lung function.
Methods: 20 patients (10 males), mean age 31 (±11) years and mean FEV1
47 (±12) % predictive completed a 3 months randomized trial comparing standard
treatment (PEP mask) with NIV-Bilevel as airway clearance technique.
Lung function test (performed 1 hour after physiotherapy), 6 min walk test, blood
gases, sputum culture and blood samples were measured before and after the
treatment period.
All patients inhaled bronchodilators and hypertonic saline during chest physiother-
apy. The treatment was performed twice a day.
Result: There was a signiﬁcant reduction in LCI following NIV compared with
PEP (p< 0.05). There were no statistical differences in FEV1 % (p = 0.81), FVC%
(p = 0.11), pCO2 (p = 0.51), and the 6 min walk test (p = 0.52) but a tendency for
better values in the NIV group regarding pCO2 and 6 min walk test.
Conclusion: NIV is a good alternative to PEP in chest physiotherapy for patients
with CF who are severe ill. The results in lung function show that LCI could be a
good alternative to evaluate the effect of physiotherapy treatment.
